Ipilimumab in Non-Small Cell Lung Cancer
|Drug class||Target||Agent||Diseases||Line of Therapy||Status||Source|
|CTLA-4 inhibitors, Immunotherapy, Monoclonal antibody||CTLA-4||ipilimumab (Yervoy)||non-small cell lung cancer||metastatic||Trials complete with results||Lynch et al. 2012|
The efficacy and safety of anti-CTLA-4 molecules for the treatment of patients with non-small cell lung cancer (NSCLC) is currently under investigation. Ipilimumab has shown promise in treating patients with metastatic NSCLC in one phase II trial (Lynch et al. 2012). This has led to ongoing phase III trials of ipilimumab in the treatment of patients with metastatic NSCLC (NCT01285609; Langer 2014).
|Reference||Study Type / Phase||Line of Treatment||Treatment Agent||Mutation Status||# Patients in Study||Response Rate||PFS (months)||OS (months)|
|Lynch et al. 2012||Phase II||1st||concurrent ipilimumab + carboplatin + paclitaxel||70||21%||4.1||9.7|
|phased ipilimumab + carboplatin + paclitaxel||68||32%||5.1||12.2|
|carboplatin + paclitaxel||66||14%||4.2||8.3|
Suggested Citation: Iams, W.T., D. Johnson, C. Lovly. 2015. Immunotherapy in Cancer. My Cancer Genome http://www.padiracinnovation.org/content/molecular-medicine/c2654-non-small-cell-lung-cancer/ (Updated February 10).
Last Updated: June 24, 2015